{"id":"W4281932311","doi":"10.1016/j.cjca.2022.05.021","title":"Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; St. Michael's Hospital; University of Alberta; University of Toronto","funders":"European Metrology Programme for Innovation and Research; American Regent; Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; Servier; Duke Clinical Research Institute; Eisai; Astellas Pharma; Uppsala Universitet; MyoKardia; Novo Nordisk; Daiichi-Sankyo; Medicines Company; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Pfizer; York University; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; European Commission; Sanofi; HLS Therapeutics; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen","keywords":"Medicine; Mace; Myocardial infarction; Internal medicine; Hazard ratio; Alirocumab; Cardiology; Unstable angina; Acute coronary syndrome; Confidence interval; Percutaneous coronary intervention; Cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001995344,0.0007912092,0.001383496,0.0005993145,0.0003525972,0.0007210191,0.0004095216,0.0004101669,0.001919117],"category_scores_gemma":[0.002358112,0.0003413388,0.002571232,0.0008395327,0.0003167414,0.0004125381,0.001020586,0.0007779285,0.000144167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003894414,"about_ca_system_score_gemma":0.0005021909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00344706,"about_ca_topic_score_gemma":0.006280485,"domain_scores_codex":[0.9988666,0.0004079362,0.0001406206,0.0002443894,0.0001688906,0.0001716435],"domain_scores_gemma":[0.9978572,0.0005194962,0.0008447766,0.000263559,0.0001837165,0.0003313582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0620482,0.000540412,0.9119461,0.0006899482,0.01011314,0.0001788767,0.0001261017,0.0003088173,0.001106682,0.0001127186,0.001363552,0.01146544],"study_design_scores_gemma":[0.006858628,0.002310432,0.983567,0.00005285571,0.004971329,0.0002667659,0.0000748007,0.0005221724,0.0002069008,0.0001322992,0.001015676,0.00002122565],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954744,0.002694356,0.000161243,0.0000784994,0.00002263387,0.00007638595,0.001095876,0.000005772667,0.0003909025],"genre_scores_gemma":[0.9972532,0.000623888,0.000162109,0.000134516,0.00007297227,0.0000900632,0.001475348,0.000004024299,0.0001838372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00344706,"threshold_uncertainty_score":0.01055247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009588145241084471,"score_gpt":0.2108200627183617,"score_spread":0.2012319174772772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}